Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Conditions
Keywords
oral contraception, Depo-Provera, Mirena
Brief summary
The investigators are conducting a research study to understand how cells responsible for fighting infection (immune cells) are affected by hormonal contraceptive use. The investigators hypothesize that progestin-containing hormonal contraceptives (i.e., Depo-Provera) inhibit host response to infection. To test this hypothesis, the investigators will collect blood and genital tract samples from women before and after their initiation of a hormonal contraceptive (either birth control pills, Depo-Provera, or Mirena).
Interventions
Sponsors
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Thomas Cherpes, DVM, MD
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
15 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
1. 15-25 years of age (inclusive) 2. History of regular menstrual cycle 3. Not pregnant 4. No plan to become pregnant in the next 3 months 5. Interested in beginning use of OC, DMPA, or LNG-IUD 6. Able to read and provide written informed consent (and consent from a parent/guardian if the participant is a minor)
Exclusion criteria
1. Anticipated move out of area that prevents return for a follow-up visit 2. Unavailability for follow-up visit 3. Less than 90 days post-partum or post-abortion 4. Sexually transmitted infection (STI) diagnosed less than 30 days prior to enrollment 5. Use of OC, contraceptive ring or patch, single rod implant, LNG-IUD, or copper-containing IUD less than 3 months prior to enrollment 6. DMPA injection less than 6 months prior to enrollment 7. History of immunosuppressive condition of current use of immunosuppressive medications 8. History of a cervical malignancy 9. Detection of cervical anatomic pathologic conditions that preclude cervical biopsy procurement 10. Intolerance or contradiction to use of OC, DMPA, or LNG-IUD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proliferative capacity (i.e., ability to respond to antigen stimulation) of T cells isolated from the cervix of women before and after initiating a hormonal contraceptive | Prior to and ~ 1 month (but up to 2 months) after initiation of a hormonal contraceptive |
Countries
United States
Outcome results
None listed